VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX
Delisted
VIRX was delisted on the 3rd of February, 2025.
42 hedge funds and large institutions have $5.61M invested in Viracta Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 6 closing their positions.
Holders
42
Holders Change
–
Holders Change %
0%
% of All Funds
0.62%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
6
Increased
9
Reduced
7
Closed
6
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
–
Top Buyers
1 |
1
UBS Group
Zurich,
Switzerland
|
$96.1K |
2 |
2
Morgan Stanley
New York
|
$99.6K |
3 |
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
$23.6K |
4 |
4
Squarepoint
New York
|
$20.6K |
5 |
5
Renaissance Technologies
New York
|
$102K |